Incidence, reversal, and prevention of opioid-induced respiratory depression

Anesthesiology

Volumn 112, Issue 1, 2010, Pages 226-238

  Dahan, Albert ^a   Aarts, Leon ^a   Smith, Terry W ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Clinical Pharmacologist   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 3 ISOPROPYL 2 OXO 1 BENZIMIDAZOLECARBOXYLIC ACID 3ALPHA TROPANYLAMIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALFENTANIL; AMPA RECEPTOR AGONIST; ANALGESIC AGENT; ANIRACITAM; BENZAMIDE; BENZOTHIADIAZIDE; BUSPIRONE; CLOZAPINE; CX 614; CX 717; FENTANYL; MINOCYCLINE; MORPHINE; MOSAPRIDE CITRATE; N [2 [4 (3 THIENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; NALOXONE; OPIATE; PLACEBO; SEROTONIN AGONIST; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG; ZACOPRIDE; BUPRENORPHINE; NARCOTIC ANTAGONIST; SEROTONIN RECEPTOR AFFECTING AGENT;

ANALGESIA; CANCER PAIN; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; FATALITY; HUMAN; INCIDENCE; LOW DRUG DOSE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NAUSEA; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RESPIRATION DEPRESSION; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; RESPIRATORY FAILURE;

BUPRENORPHINE; HUMANS; MINOCYCLINE; NALOXONE; NARCOTIC ANTAGONISTS; POSTOPERATIVE COMPLICATIONS; RESPIRATORY INSUFFICIENCY; SEROTONIN AGENTS;

EID: 74049120335     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181c38c25     Document Type: Review

References (117)

1. Macario A, Pergolizzi JV: Pain and nausea management after surgery. Int J Pain Med Pall Care 2004; 3:91-100
2. Sydow M, Neumann P: Sedation for the critically ill. Intensive Care Med 1999; 25:634-636
3. Bovill JG: Opium: A drug ancient and modern, Advances in Anesthesia and Analgesia: 22 Years of Research in Anesthesiology at Leiden University and LUMC. Edited by Dahan A, van Kleef JW. Leiden, Department of Anesthesiology (LUMC), 2007, pp 13-27
4. Serturner F: Uber das Morphium, eine neue salzfahige Grundlage, und die Mekonsaure, als Hauptbestandtheile des Opiums. Annalen der Physik 1817; 5:56-75
5. Huxtable RJ, Schwarz SK: The isolation of morphine. Mol Interv 2001; 1:189-191
6. Martin WR: Opioid antagonists. Pharmacol Rev 1967; 19:463-521
7. Dahan A, Sarton E, Teppema L, Olievier C, Nieuwenhuijs D, Matthes HWD, Kieffer BL: Anesthetic potency and influence of morphine and sevoflurane on respiration in /n-opioid receptor knockout mice. ANESTHESIOLOGY 2001; 94:824-832
8. Romberg R, Sarton E, Teppema L, Matthes H, Kieffer B, Dahan A: No difference between morphine and mor-phine-6-glucuronide on respiration in /n-opioid receptor-deficient mice. Br J Anaesth 2003; 91:862-870
9. van Dorp E, Yassen A, Dahan A: Naloxone treatment in opioid addiction: The risks and benefits. Expert Opin Drug Saf 2007; 6:125-132
10. Zuurmond WW, Meert TF, Noorduin H: Partial versus full agonists for opioid-mediated analgesia focus on fentanyl and buprenorphine. Acta Anaesthesiol Belg 2002; 53: 193-201
11. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M: Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005; 94:825-834
12. Wheatley RG, Somerville ID, Sapsford DJ, Jones JG: Postoperative hypoxaemia: Comparison of extradural, i.m. and patient-controlled opioid analgesia. Br J Anaesth 1990; 64:267-275
13. Madej TH, Wheatley RG, Jackson IJ, Hunter D: Hypoxae-mia and pain relief after lower abdominal surgery: Comparison of extradural and patient-controlled analgesia: Br J Anaesth 1992; 69:554-557
14. Wheatley RG, Shepherd D, Jackson IJ, Madej TH, Hunter D: Hypoxaemia and pain relief after upper abdominal surgery: comparison of i.m. and patient-controlled analgesia. Br J Anaesth 1992; 69:558-561
15. Cole PJ, Craske DA, Wheatley RG: Efficacy and respiratory effects of low-dose spinal morphine for postoperative analgesia following knee arthroplasty. Br J Anaesth 2001; 85:233-237
16. Catley DM, Thornton C, Jordan C, Lehane JR, Royston D, Jones JG: Pronounced, episodic oxygen desaturation in the postoperative period: Its association with ventilatory pattern and analgesic regime. ANESTHESIOLOGY 1985; 63: 20-28
17. Dahan A, Teppema LJ: Influence of anaesthesia and analgesia on the control of breathing. Br J Anaesth 2003; 91:40-49 (Pubitemid 36857314)
18. Cashman JN, Dolins SJ: Respiratory and haemodynamic effects of acute postoperative pain management: Evidence from published data. Br J Anaesth 2004; 93:212-223
19. McQuay HJ, Moore RA: Postoperative analgesia and vomiting, with special reference to day-case surgery: A systematic review. Health Technol Assess 1998; 2:1-12
20. Tveita T, Thoner J, Klepstad P, Dale O, Jystad A, Borch-grevink PC: A controlled comparison between single doses of intravenous morphine with respect to analgesic effects and patient safety. Acta Anaesthesiol Scand 2008; 52:920-925
21. Sarma VJ, Bostrum UV: Intrathecal morphine for the relief of post hysterectomy pain-A double blind dose response study. Acta Anaesthesiol Scand 1993; 37:223-227
22. Jacobsen L, Chabal C, Brody MC: A dose-response study of intrathecal morphine: Efficacy, duration, optimum dose, and side effects. Anaesth Analg 1988; 67:1082-1088
23. Rawal N, Arnér S, Gustafsson LL, Allvin R: Present state of extradural and intrathecal opioid analgesia in Sweden. A nationwide follow-up survey. Br J Anaesth 1987; 59:791-799
24. Ready LB, Loper KA, Nessly M, Wild L: Postoperative epidural morphine is safe on surgical wards. ANESTHESIOLOGY 1991; 75:452-456
25. Momeni M, Crucitti M, de Kock M: Patient-controlled analgesia in the management of post-operative pain. Drugs 2006; 66:2321-2337
26. Macintyre PE, Runciman WB, Webb RK: An acute pain service in an Australian teaching hospital: The first year. Med J Aust 1990; 153:417-421
27. Wheatley RG, Madej TH, Jackson IJB, Hunter D: The first year's experience of an acute pain service. Br J Anaesth 1991; 67:353-359
28. Fleming BM, Coombes DW: A survey of complications documented in a quality-control analysis of patient-controlled analgesia in the postoperative patient. J Pain Symptom Manage 1992; 7:463-469
29. Schug SA, Torrie JJ: Safety assessment of postoperative pain management by an acute pain service. Pain 1993; 55:387-391
30. Etches RC: Respiratory depression associated with patient-controlled analgesia: A review of eight cases. Can J Anaesth 1994; 41:125-132
31. Sidebotham D, Dijkhuizen RJ, Schug SA: The safety and utilization of patient-controlled analgesia. J Pain Symptom Manage 1997; 14:202-209
32. Syed S, Paul JE, Hueftlein M, Kampf M, McLean RF: Morphine overdose from error propagation on an acute pain service. Can J Anesth 2006; 53:586-590
33. Hanna MH, Elliott KM, Fung M: Randomised, double-blind study of the analgesic efficacy of morphine-6-glucuronide versus morphine sulfate for postoperative pain in major surgery. ANESTHESIOLOGY 2005; 102:815-821
34. Goodman AJ, Le Bourdonnec B, Dolle RE: Mu opioid receptor antagonists: Recent developments. Chem Med Chem 2007; 2:1552-1570
35. Longnecker DE, Grazis PA, Eggars GWN Jr: Naloxone for antagonism of morphine-induced respiratory depression. Anesth Analg 1973; 52:447-453
36. Johnstone RE, Jobes DR, Kennell EM, Behar MG, Smith TC: Reversal of morphine anesthesia with naloxone. ANESTHESIOLOGY 1974; 41:361-367
37. Megarbane B, Decleves X, Bloch V, Bardin C, Chast F, Baud FJ: Case report: Quantification of methadone induced respiratory depression using toxicokinetic/toxico-dynamic relationships. Critical Care 2007; 11:R5
38. Martin W: Naloxone. Arch Int Med 1976; 85:765-768
39. 2 in man of intravenous naloxone measured by reversal of morphine-depressed respiration. J Pharmacol Exp Ther 1981; 219:156-162 (Pubitemid 11018644)
40. Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S: Pharmacokinetics of naloxone in rats and in man: Basis for its potency and short duration of action. ANESTHESIOLOGY 1976; 44:398-401
41. van Dorp E, Yassen A, Sarton E, Romberg R, Olofsen E, Teppema L, Danhof M, Dahan A: Naloxone reversal of buprenorphine-induced respiratory depression. ANESTHESIOLOGY 2006; 105:51-57
42. McGilliard KL, Takemori AE: Antagonism by naloxone of narcotic-induced respiratory depression and analgesia. J Pharmacol Exp Ther 1978; 207:494-503
43. Cassel JA, Daubert JD, DeHaven RN: Alvimopan binding to the micro opioid receptor: Comparative binding kinetics of opioid antagonists. Eur J Pharmacol 2005; 520: 29-36
44. Weinstein SH, Pfeiffer M, Schor JM: Metabolism and pharmacokinetics of naloxone. Psychopharmacol 1973; 8:525-535
45. Yassen A, Olofsen E, van Dorp E, Sarton E, Teppema L, Danhof M, Dahan A: Mechanism-based pharmacokinetic-pharmacodynamic modeling of the reversal of buprenorphine-induced respiratory depression by naloxone. Clin Pharmacokinet 2007; 46:966-980
46. Lotsch J: Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005; 29:S90-103
47. Sarton E, Teppema L, Dahan A: Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. Adv Exp Med Biol 2008; 605:486-491
48. Amin HM, Sopchak AM, Esposito BF, Henson LG, Baten-horst RL, Fox AW, Camporesi EM: Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil. J Pharm Exp Ther 1995; 274: 34-39
49. Shupak RC, Harp JR: Comparison between high-dose sufentail-oxygen and high-dose fentanyl-oxygen for neu-roanalgesia. Br J Anaesth 1985; 57:375-381
50. Takahashi M, Sugiyama K, Hori M, Chiba S, Kusaka K: Naloxone reversal of opioid anesthesia revisited: Clinical evaluation and plasma concentration analysis of continuous naloxone infusion after anesthesia with high-dose fentanyl. J Anesth 2004; 18:1-8
51. Kapila A, Glass PS, Jacobs JR, Muir KT, Hermann DJ, Shiraishi M, Howell S, Smith RL: Measured context-sensitive half-times of remifentanil and alfentanil. ANESTHESIOLOGY 1995; 83:968-975
52. Choi SH, Koo B-N, Nam SH, Lee SJ, Kim KJ, Kil HK, Lee K-J, Jeon DH: Comparison of remifentanil and fentanyl for postoperative pain control after abdominal hysterectomy. Yonsei Med J 2008; 49:204-210
53. Bouillon T, Bruhn J, Radu-Radulescu L, Andresen C, Co-hane C, Shafer SL: A model of the ventilatory depressant potency of remfentanil in the non-steady state. ANESTHESIOLOGY 2003; 99:779-787
54. Gross JB: When you breathe IN you inspire, when you DON'T breathe you. expire: New insights regarding opioid-induced ventilatory depression. ANESTHESIOLOGY 2003; 99:767-770
55. Knape JTA: Early respiratory depression resistant to nal-oxone following epidural buprenorphine. ANESTHESIOLOGY 1986; 64:382-384
56. Orwin J: Pharmacological aspects of buprenorphine in man, New Perspectives in Measurement and Management of Pain. Edited by Hyams AW, Smith R, Whittle B. Edinburgh, Churchill Livingstone, 1977, pp 139-159
57. Heel RC, Brodgen RN, Speight TM, Avery GS: Buprenor-phine: A review of its pharmacologic properties and therapeutic efficacy. Drugs 1979; 18:81-110
58. Gal TJ: Naloxone reversal of bupreorphine-induced respiratory depression. Clin Pharmacol Ther 1989; 45:66-71
59. Bullingham RES, McQuay HJ, Moore A, Bennett MRD: Buprenorphine kinetics. Clin Pharmacol Ther 1980; 28: 667-672
60. Boas RA, Villiger JW: Clinical actions of fentanyl and buprenorphine: The significance of receptor binding. Br J Anaesth 1985; 57:192-196
61. Cowan A, Friderichs E, Strassburger W, Raffa RB: Basic pharmacology of buprenorphine. Buprenorphine: The Unique Opioid Analgesic. Edited by Budd K, Raffa RB. Stuttgart, Vertag KG, 2005, pp 3-21
62. Yassen A, Olofsen E, Kan J, Dahan A, Danhof M: Animal-to-human extrapolation of the pharmacokinetic and phar-macodynamic properties of buprenorphine. Clin Phar-mackinet 2007; 46:433-447
63. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maid-ment NT, Evans CJ: Buprenorphine-induced antinocicep-tion is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 2003; 23:10331-10337
64. Flacke JW, Facke WE, Williams GD: Acute pulmonary edema following naloxone reversal of high-dose morphine anesthesia. ANESTHESIOLOGY 1977; 47:376-378
65. Michaelis LL, Hickey PR, Clark TL: Ventricular irritability associated with the use of naloxone. Ann Thoracic Surg 1974; 18:608-614
66. Tanaka GY: Hypertensive reaction to naloxone. JAMA 1974; 228:25-26
67. Taff RH: Pulmonary edema following naloxone administration in a patient without heart disease. ANESTHESIOLOGY 1983; 59:576-577
68. Partridge BL, Ward CF: Pulmonary edema following low-dose naloxone administration. ANESTHESIOLOGY 1986; 65: 709-710
69. Osterwalder JJ: Naloxone for intoxications with intravenous heroin and heroin mixtures-Harmless or hazardous? J Toxicol Clin Toxicol 1996; 34:409-416
70. Pattinson KTS: Opioids and the control of respiration. Br J Anaesth 2008; 100:747-758
71. Richter DW, Manzke T, Wilken B, Ponimaskin E: Serotonin receptors: Guardians of stable breathing. Trends Mol Med 2003; 9:542-548
72. Smith JC, Ellenberger HH, Ballanyi K, Richter DW, Feld-man JL: Pre-Bötzinger complex: A brainstem region that may generate respiratory rhythm in mammals. Science 1991; 254:726-729
73. Reckling JC, Feldman JL: Pre-Bötzinger complex and pacemaker neurons: Hypothesized site and kernel for respiratory rhythm generation. Annu Rev Physiol 1998; 60:385-405
74. Smith JC, Butera RJ, Koshiya N, Del Negro C, Wilson CG, Johnson SM: Respiratory rhythm generation in neonatal and adult mammals: The hybrid pacemaker network model. Respir Physiol 2000; 122:131-147
75. 1A receptors. J Pharmacol Exp Ther 2000; 292:704-713
76. Meyer LCR, Fuller A, Mitchell D: Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats. Am J Physiol Regul Integr Comp Physiol 2006; 290:R405-13
77. Wang X, Dergacheva O, Kamendi H, Gorini C, Mende-lowitz D: 5-hydroxytryp-tamine 1A/7 and 4a receptors differentially prevent opioid-induced inhibition of brain stem cardiorespiratory function. Hypertension 2007; 50: 368-376
78. Yamauchi M, Dostal J, Kimura H, Strohl KP: Effects of buspirone on posthypoxic ventilatory behavior in the C57BL/6J and A/J mouse strains. J Appl Physiol 2008; 105:518-526
79. Guenther U, Manzke T, Wrigge H, Dutschmann M, Zin-serling J, Putensen C, Hoeft A: The counteraction of opioid-induced ventilatory depression by the serotonin 1A-agonist 8-OH-DPAT does not antagonize antinocicep-tion in rats in situ and in vivo. Anesth Analg 2009; 108:1169-1176
80. Pierrefiche O, Schwarzacher SW, Bischoff AM, Richter DW: Blockade of synaptic inhibition within the pre-Bötz-inger complex in the cat suppresses respiratory rhythm generation in vivo. J Physiol 1998; 509:245-254
81. Feldman JL, Del Negro CA: Looking for inspiration: New perspectives on respiratory rhythm. Nat Rev Neurosci 2006; 7:232-242
82. Janczewski WA, Feldman JL: Distinct rhythm generators for inspiration and expiration in the juvenile rat. J Physiol 2006; 570:407-420
83. Barnes NM, Sharp T: A review of central 5HT receptors and their function. Neuropharmacology 1999; 38:1083-1152
84. Lalley PM, Bischoff AM, Richter DW: 5HT-1A receptor mediated modulation of medullary expiratory neurons in the cat. J Physiol 1994; 476:117-130
85. Lalley PM, Bischoff AM, Richter DW, Lalley PM, Benaeker R: Nucleus raphe obscurus evokes 5HT-1A receptor-mediated modulation of respiratory neurons. Brain Res 1997; 747:156-159
86. Teng YD, Bingaman M, Taveira-DaSilva AM, Pace PP, Gillis RA, Wrathall JR: Serotonin 1A receptor agonists reverse respiratory abnormalities in spinal cord-injured rats. J Neurosci 2003; 23:4182-4189
87. Alexander SP, Mathie A, Peters JA: Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 2008; 153(Suppl 2):S1-207
88. Wilken B, Lalley P, Bischoff AM, Christen HJ, Behnke J, Hanefeld F, Richter DW: Treatment of apneustic respiratory disturbance with a serotonin-receptor agonist. J Pe-diatr 1997; 130:89-94
89. Andaku DK, Mercadante MT, Schwartzman JS: Buspirone in Rett syndrome respiratory dysfunction. Brain Dev 2005; 27:437-438
90. El-Khatib MF, Kiwan RA, Jamaleddine GW: Buspirone treatment for apneustic breathing in brain stem infarct. Respir Care 2003; 48:956-958
91. 1A receptor agonist buspirone does not antagonize morphine-induced respiratory depression in humans. Clin Pharmacol Ther 2007; 81:59-68
92. Manzke T, Guenther U, Ponimaskin EG, Haller M, Dutschmann M, Schwarzacher S, Richter DW: 5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia. Science 2003; 301:226-229
93. Manzke T, Preusse S, Richter DW: Developmental changes of serotonin 4 (a) receptor expression in the rat pre-Bötzinger complex. J Comp Neurol 2008; 506:775-790
94. Ballanyi K, Lalley PM, Hoch B, Richter DW: cAMP-depen-dent reversal of opioid and prostaglandin-mediated depression of the isolated respiratory network in newborn rats. J Physiol 1997; 504:127-134
95. Lotsch J, Skarke C, Schneider A, Hummel T, Geisslinger G: The 5-hydroxytryptamine 4 receptor agonist mosa-pride does not antagonize morphine-induced respiratory depression. Clin Pharmacol Ther 2005; 78:278-287
96. Kew JN, Kemp JA: Ionotropic and metabotropic gluta-mate receptor structure and pharmacology. Psychophar-macology 2005; 179:4-29
97. Black MD: Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology 2005; 179:154-163
98. Lynch G: Glutamate-based therapeutic approaches: Am-pakines. Curr Opin Pharmacol 2006; 6:82-88
99. Greer JJ, Smith JC, Feldman JL: The role of excitatory amino acids in the generation and transmission of respiratory drive in the neonatal rat. J Physiol 1991; 437: 727-749
100. Funk GD, Smith JC, Feldman JL: Generation and transmission of respiratory oscillations in medullary slices: Role of excitatory amino acids. J Neurophysiol 1993; 70:1497-1515
101. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES: AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord 2004; 3:181-194
102. Aria AC, Xia Y-F, Rogers G, Lynch G, Kessler M: Benz-amide-type AMPA receptor modulators form two subfamilies with distinct modes of action. J Pet Exp Pharmacol 2002; 303:1075-1085
103. Nagarajan N, Quast C, Boxall AR, Shahid M, Rosenmund C: Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546. Neuropharmacology 2001; 41:650-663
104. Aria AC, Xia Y-F, Suzuki E: Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. Neuroscience 2004; 123:1011-1024
105. Jin R, Clarke S, Weeks A, Dudman J, Gouaux E, Partin K: Mechanism of positive allosteric modulators acting on AMPA receptors. J Neuroscience 2005; 25:9027-9036
106. Ren J, Poon BY, Tang Y, Funk GD, Greer JJ: Amkakines alleviate respiratory depression in rats. Am J Respir Crit Care Med 2006; 174:1384-1391
107. Ren J, Ding X, Funk GD, Greer JJ: Ampakine CX717 protects against fentanyl-induced respiratory depression and lethal ap-nea in rats. ANESTHESIOLOGY 2009; 110:1364-1370
108. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G: A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21:484-487
109. Pellerin L, Magistretti PJ: Ampakine CX546 bolsters energetic response of astrocytes: A novel target for cognitive-enhancing drugs acting as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropi-onic acid (AMPA) receptor modulators. J Neurochem 2005; 92:668-677
110. Dahan A, Smith TW: Opioids and the immune system. Ned Tijdsch Anesthesiol 2008; 20:14-18
111. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR: Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence and reward. ScientificWorldJournal 2007; 7:98-111
112. Cui Y, Liao XX, Liu W, Guo RX, Wu ZZ, Zhao CM, Chen PX, Feng JQ: A novel role of minocycline: Attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav Im-mun 2008; 22:114-123
113. Hutchinson MR, Northcutt AL, Chao LW, Kearney JL, Zhang Y, Berkelhammer DL, Loram LC, Rozeske RR, Bland ST, Maier SF, Gleeson TT, Watkins LR: Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun 2008; 22:1248-1256
114. Berkenbosch A, Teppema LJ, Olievier CN, Dahan A: Influences of morphine on the ventilatory response to isocapnic hypoxia. ANESTHESIOLOGY 1997; 86:1342-1349
115. Lötsch J, Dudziak R, Freynhagen R, Marschner J, Gei-sslinger G: Fatal respiratory depression after multiple intravenous morphine injections. Clin Pharmacokinet 2006; 45:1051-1060
116. Kiwull-Schöne H, Kiwull P, Frede S, Wiemann M: Role of brainstem sodium/proton exchanger 3 for breathing control during chronic acid-base imbalance. Am J Respir Crit Care Med 2007; 176:513-519
117. Wiemann M, Piechatzek L, Göpelt K, Kiwull-Schöne H, P. Kiwull, Bingman D: The NHE3 inhibitor AVE1599 stimulates phrenic nerve activity in the rat. J Physiol Pharmacol 2008; 59:27-36